Ophthalmology

EMA Begins Review of Samsung Bioepis' Ranibizumab

October 6th 2020

By Tony Hagen

The European Medicines Agency (EMA) regulatory review advances a pact between Samsung Bioepis and Biogen announced last year.

California's Governor Signs Bill for State to Produce Its Own Biosimilars, Insulins

September 29th 2020

By Skylar Jeremias

Article

California has become the first state to implement a policy to produce and distribute its own drug products to help lower costs.

Stakeholders Joust Over Biosimilar Availability at PCOC20

September 25th 2020

By Tony Hagen

Article

A diverse panel from practice, payer, and wholesale perspectives convened at The American Journal of Managed Care®'s Patient-Centered Oncology Care® 2020 virtual conference to hash out one of the hottest issues in biosimilar availability right now.

Report: PBM "Reforms" Leave Biosimilars Out in the Cold

September 2nd 2020

By Tony Hagen

Article

It’s same old, same old when it comes to pharmacy benefit manager (PBM) contracts despite much touted reforms, authors of a review contend.

Investigators Eye Gaps in Biosimilar Assessment Reports

August 31st 2020

By Deana Ferreri, PhD

Article

Health technology tssessments play an important role in building confidence for use of biosimilars, yet very few meet criteria for thoroughness.

Formycon, Bioeq Enroll First Patient in Phase 3 Aflibercept Study

August 24th 2020

By Tony Hagen

Article

Multiple contenders are lining up for the pending expiration of patents on the blockbuster Regeneron reference product for wet age-related macular degeneration.

Winegarden: Biosimilars Market Lacks Oomph

August 17th 2020

By Tony Hagen

Article

A Pacific Research Institute economist says that by his scorecard, biosimilars are not supercharging the market the way they ought to be doing .

Pfizer Expert Urges Employers to Get Proactive on Biosimilars

August 13th 2020

By Tony Hagen

Article

Defining biosimilar use in the United States as "sluggish," Juliana Reed, MS, said employers have to get involved.

Samsung Bioepis Enters Breast and Gastric Market in Brazil

August 10th 2020

By Tony Hagen

Article

Samsung Bioepis makes a move into the promising Brazilian market for biosimilars, which data suggest is one of the fastest-growing biosimilars markets among emerging nations.

ASCO Study: Mandatory Drug Licensing Can Bridge Care Divide

August 5th 2020

By Skylar Jeremias

Article

Biosimilars have improved access to health care in India, but many effective new drugs are high priced and patented, and authors of a new study recommend interventions to make these available, too.